In mid-March this year, supplementary protection certificates (SPCs) protecting Johnson & Johnson’s Zytiga (abiraterone acetate) blockbuster will expire in most Western European countries. These SPCs are based on European compound patent EP0,633,893 and its national counterparts.
However, IQVIA, which maintains the Ark Patent Intelligence Expiry Database, points out that SPC expiry will not immediately open the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?